A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Raymund R. Razonable; Nicole C.E. Aloia; Ryan J. Anderson; Gokhan Anil; Lori L. Arndt; Richard F. Arndt; Sara E. Ausman; Sarah J. Bell; Dennis M. Bierle; Marcie L. Billings; Rachel K. Bishop; Carl H. Cramer; Tracy L. Culbertson; Ala S. Dababneh; Amber N. Derr; Kevin Epps; Susan M. Flaker; Ravindra Ganesh; Mary A. Gilmer; Eric Gomez Urena; Christopher R. Gulden; Tamara L. Haack; Sara N. Hanson; Jenna R. Herzog; Alexander Heyliger; Lex D. Hokanson; Laura H. Hopkins; Richard J. Horecki; Bipinchandra Hirisave Krishna; W. Charles Huskins; Tammy A. Jackson; Ryan R. Johnson; Betty Jorgenson; Cory Kudrna; Brian D. Kennedy; Mary K. Klingsporn; Brian Kottke; Jennifer J. Larsen; Sarah R. Lessard; Larry I. Lutwick; Edward J. Malone; Jennifer A. Matoush; Ivana N. Micallef; Darcie E. Moehnke; Muhanad Mohamed; Colleena N. Ness; Shelly M. Olson; Robert Orenstein; Raj Palraj; Janki Patel; Damian J. Paulson; David Phelan; Margaret T. Peinovich; Wilford L. Ramsey; Taunya J. Rau-Kane; Kevin I. Reid; Karen J. Reinschmidt; Maria Teresa Seville; Erin C. Skold; Jill M. Smith; Leigh L. Speicher; Laurie A. Spielman; Donna J. Springer; Perry W. Sweeten; Jennifer M. Tempelis; Sidna Tulledge-Scheitel; Paschalis Vergidis; Daniel C. Whipple; Caroline G. Wilker; Molly J. Destro Borgen

doi:10.1016/j.mayocp.2021.03.010

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson, Gokhan Anil, Lori L. Arndt, Richard F. Arndt, Sara E. Ausman, Sarah J. Bell, Dennis M. Bierle, Marcie L. Billings, Rachel K. Bishop, Carl H. Cramer, Tracy L. Culbertson, Ala S. Dababneh, Amber N. Derr, Kevin Epps, Susan M. Flaker, Ravindra Ganesh, Mary A. Gilmer, Eric Gomez UrenaChristopher R. Gulden, Tamara L. Haack, Sara N. Hanson, Jenna R. Herzog, Alexander Heyliger, Lex D. Hokanson, Laura H. Hopkins, Richard J. Horecki, Bipinchandra Hirisave Krishna, W. Charles Huskins, Tammy A. Jackson, Ryan R. Johnson, Betty Jorgenson, Cory Kudrna, Brian D. Kennedy, Mary K. Klingsporn, Brian Kottke, Jennifer J. Larsen, Sarah R. Lessard, Larry I. Lutwick, Edward J. Malone, Jennifer A. Matoush, Ivana N. Micallef, Darcie E. Moehnke, Muhanad Mohamed, Colleena N. Ness, Shelly M. Olson, Robert Orenstein, Raj Palraj, Janki Patel, Damian J. Paulson, David Phelan, Margaret T. Peinovich, Wilford L. Ramsey, Taunya J. Rau-Kane, Kevin I. Reid, Karen J. Reinschmidt, Maria Teresa Seville, Erin C. Skold, Jill M. Smith, Leigh L. Speicher, Laurie A. Spielman, Donna J. Springer, Perry W. Sweeten, Jennifer M. Tempelis, Sidna Tulledge-Scheitel, Paschalis Vergidis, Daniel C. Whipple, Caroline G. Wilker, Molly J. Destro Borgen

Research output: Contribution to journal › Article › peer-review

Abstract

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.

Original language	English (US)
Pages (from-to)	1250-1261
Number of pages	12
Journal	Mayo Clinic proceedings
Volume	96
Issue number	5
DOIs	https://doi.org/10.1016/j.mayocp.2021.03.010
State	Published - May 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2021.03.010

Cite this

Razonable, R. R., Aloia, N. C. E., Anderson, R. J., Anil, G., Arndt, L. L., Arndt, R. F., Ausman, S. E., Bell, S. J., Bierle, D. M., Billings, M. L., Bishop, R. K., Cramer, C. H., Culbertson, T. L., Dababneh, A. S., Derr, A. N., Epps, K., Flaker, S. M., Ganesh, R., Gilmer, M. A., ... Destro Borgen, M. J. (2021). A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model. Mayo Clinic proceedings, 96(5), 1250-1261. https://doi.org/10.1016/j.mayocp.2021.03.010

Razonable, RR, Aloia, NCE, Anderson, RJ, Anil, G, Arndt, LL, Arndt, RF, Ausman, SE, Bell, SJ, Bierle, DM, Billings, ML, Bishop, RK, Cramer, CH, Culbertson, TL, Dababneh, AS, Derr, AN, Epps, K, Flaker, SM, Ganesh, R, Gilmer, MA, Urena, EG, Gulden, CR, Haack, TL, Hanson, SN, Herzog, JR, Heyliger, A, Hokanson, LD, Hopkins, LH, Horecki, RJ, Krishna, BH, Huskins, WC, Jackson, TA, Johnson, RR, Jorgenson, B, Kudrna, C, Kennedy, BD, Klingsporn, MK, Kottke, B, Larsen, JJ, Lessard, SR, Lutwick, LI, Malone, EJ, Matoush, JA, Micallef, IN, Moehnke, DE, Mohamed, M, Ness, CN, Olson, SM, Orenstein, R, Palraj, R, Patel, J, Paulson, DJ, Phelan, D, Peinovich, MT, Ramsey, WL, Rau-Kane, TJ, Reid, KI, Reinschmidt, KJ, Seville, MT, Skold, EC, Smith, JM, Speicher, LL, Spielman, LA, Springer, DJ, Sweeten, PW, Tempelis, JM, Tulledge-Scheitel, S, Vergidis, P, Whipple, DC, Wilker, CG & Destro Borgen, MJ 2021, 'A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model', Mayo Clinic proceedings, vol. 96, no. 5, pp. 1250-1261. https://doi.org/10.1016/j.mayocp.2021.03.010

@article{0b7919c642354febbeac3c4125a8f1d8,

title = "A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model",

abstract = "The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.",

author = "Razonable, {Raymund R.} and Aloia, {Nicole C.E.} and Anderson, {Ryan J.} and Gokhan Anil and Arndt, {Lori L.} and Arndt, {Richard F.} and Ausman, {Sara E.} and Bell, {Sarah J.} and Bierle, {Dennis M.} and Billings, {Marcie L.} and Bishop, {Rachel K.} and Cramer, {Carl H.} and Culbertson, {Tracy L.} and Dababneh, {Ala S.} and Derr, {Amber N.} and Kevin Epps and Flaker, {Susan M.} and Ravindra Ganesh and Gilmer, {Mary A.} and Urena, {Eric Gomez} and Gulden, {Christopher R.} and Haack, {Tamara L.} and Hanson, {Sara N.} and Herzog, {Jenna R.} and Alexander Heyliger and Hokanson, {Lex D.} and Hopkins, {Laura H.} and Horecki, {Richard J.} and Krishna, {Bipinchandra Hirisave} and Huskins, {W. Charles} and Jackson, {Tammy A.} and Johnson, {Ryan R.} and Betty Jorgenson and Cory Kudrna and Kennedy, {Brian D.} and Klingsporn, {Mary K.} and Brian Kottke and Larsen, {Jennifer J.} and Lessard, {Sarah R.} and Lutwick, {Larry I.} and Malone, {Edward J.} and Matoush, {Jennifer A.} and Micallef, {Ivana N.} and Moehnke, {Darcie E.} and Muhanad Mohamed and Ness, {Colleena N.} and Olson, {Shelly M.} and Robert Orenstein and Raj Palraj and Janki Patel and Paulson, {Damian J.} and David Phelan and Peinovich, {Margaret T.} and Ramsey, {Wilford L.} and Rau-Kane, {Taunya J.} and Reid, {Kevin I.} and Reinschmidt, {Karen J.} and Seville, {Maria Teresa} and Skold, {Erin C.} and Smith, {Jill M.} and Speicher, {Leigh L.} and Spielman, {Laurie A.} and Springer, {Donna J.} and Sweeten, {Perry W.} and Tempelis, {Jennifer M.} and Sidna Tulledge-Scheitel and Paschalis Vergidis and Whipple, {Daniel C.} and Wilker, {Caroline G.} and {Destro Borgen}, {Molly J.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = may,

doi = "10.1016/j.mayocp.2021.03.010",

language = "English (US)",

volume = "96",

pages = "1250--1261",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "5",

}

TY - JOUR

T1 - A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

T2 - The Mayo Clinic Model

AU - Razonable, Raymund R.

AU - Aloia, Nicole C.E.

AU - Anderson, Ryan J.

AU - Anil, Gokhan

AU - Arndt, Lori L.

AU - Arndt, Richard F.

AU - Ausman, Sara E.

AU - Bell, Sarah J.

AU - Bierle, Dennis M.

AU - Billings, Marcie L.

AU - Bishop, Rachel K.

AU - Cramer, Carl H.

AU - Culbertson, Tracy L.

AU - Dababneh, Ala S.

AU - Derr, Amber N.

AU - Epps, Kevin

AU - Flaker, Susan M.

AU - Ganesh, Ravindra

AU - Gilmer, Mary A.

AU - Urena, Eric Gomez

AU - Gulden, Christopher R.

AU - Haack, Tamara L.

AU - Hanson, Sara N.

AU - Herzog, Jenna R.

AU - Heyliger, Alexander

AU - Hokanson, Lex D.

AU - Hopkins, Laura H.

AU - Horecki, Richard J.

AU - Krishna, Bipinchandra Hirisave

AU - Huskins, W. Charles

AU - Jackson, Tammy A.

AU - Johnson, Ryan R.

AU - Jorgenson, Betty

AU - Kudrna, Cory

AU - Kennedy, Brian D.

AU - Klingsporn, Mary K.

AU - Kottke, Brian

AU - Larsen, Jennifer J.

AU - Lessard, Sarah R.

AU - Lutwick, Larry I.

AU - Malone, Edward J.

AU - Matoush, Jennifer A.

AU - Micallef, Ivana N.

AU - Moehnke, Darcie E.

AU - Mohamed, Muhanad

AU - Ness, Colleena N.

AU - Olson, Shelly M.

AU - Orenstein, Robert

AU - Palraj, Raj

AU - Patel, Janki

AU - Paulson, Damian J.

AU - Phelan, David

AU - Peinovich, Margaret T.

AU - Ramsey, Wilford L.

AU - Rau-Kane, Taunya J.

AU - Reid, Kevin I.

AU - Reinschmidt, Karen J.

AU - Seville, Maria Teresa

AU - Skold, Erin C.

AU - Smith, Jill M.

AU - Speicher, Leigh L.

AU - Spielman, Laurie A.

AU - Springer, Donna J.

AU - Sweeten, Perry W.

AU - Tempelis, Jennifer M.

AU - Tulledge-Scheitel, Sidna

AU - Vergidis, Paschalis

AU - Whipple, Daniel C.

AU - Wilker, Caroline G.

AU - Destro Borgen, Molly J.

PY - 2021/5

Y1 - 2021/5

N2 - The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.

AB - The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.

UR - http://www.scopus.com/inward/record.url?scp=85105452411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105452411&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2021.03.010

DO - 10.1016/j.mayocp.2021.03.010

M3 - Article

C2 - 33958056

AN - SCOPUS:85105452411

SN - 0025-6196

VL - 96

SP - 1250

EP - 1261

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 5

ER -

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this